Bill · H.R. 1143· House(119-HR-1143)
Medicare IVIG Access Enhancement Act of 2025
- Introduced
- 2/7/2025
- Last activity
- 2/7/2025 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Sponsored by
- Adrian Smith
- Cosponsors
- - 0 - 2
- Introduced
- In Committee
What this bill would do
This bill, known as the "Medicare IVIG Access Enhancement Act of 2025," aims to amend the Social Security Act. The primary goal is to expand Medicare coverage for the in-home administration of intravenous immune globulin. This expansion specifically targets the treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. The changes are set to begin on January 1, 2027. It also allows for variances in payments regarding these treatments.
Yes· 3 of 7
Would people with disabilities be better off under this?+5
The bill improves access to essential in-home medical treatment for those suffering from chronic neurological conditions.
Does this make health care easier to get in general?+5
The bill expands access to in-home administration of intravenous immune globulin for patients with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Would people over 65 be better off under this?+4
The bill expands Medicare benefits which primarily serves the senior population.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Expanded Medicare Coverage: The bill expands coverage for the in-home administration of intravenous immune globulin for those with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy (Section 2(a)). This allows specific groups of people to receive treatment at home under the Medicare program.
-
Payment Variance Authority: The Secretary is given the authority to vary payments depending on whether the administration is for a primary immune deficiency disease or the newly added conditions (Section 2(b)). This provides a mechanism for adjusting payments as determined appropriate through rulemaking.
Potential Negative Impacts for People
- Delayed Implementation: The expanded coverage for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy does not begin until January 1, 2027 (Section 2(a)). This means individuals currently facing these conditions must wait for the coverage to take effect.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For People With Disabilities+5Good For Retirees+4Good For Seniors+4Good For Low Income Households+3Good For Middle Class Households+3
- Healthcare
- Improves Healthcare Access+5Increases Medicare Funding+3
- 11/4/2025
- 1 Cosponsor added.
- 2/7/2025
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 1 Cosponsor added.
- Introduced in House
John GaramendiDemocrat · California
Eugene VindmanDemocrat · Virginia